Fecal microbiota transplant was noninferior to vancomycin as the initial treatment for C. diff in a randomized, open-label trial. Transplant showed slightly higher cure rates without recurrence and ...

Four things you need to know: 1. A team of researchers led by Michael Bretthauer, MD, PhD, a gastroenterologist at the University of Oslo in Norway, conducted the study at six Norwegian hospitals ...

A fecal microbiota transplant (FMT) not only cured a case of Clostridium difficile (C. diff) infection in a 66 year old man; it eliminated populations of multi-drug resistant organisms both in the ...

Q: I was sick for months with debilitating pain, extreme weight loss, fatigue and loss of appetite. I was diagnosed with C. diff related to an abdominal surgery. I’m being treated with antibiotics, ...

Traditional vs. novel therapy Fecal microbiota transplant has been used as the traditional treatment for C. diff. infection for a little over a decade. The procedure, which is done via colonoscopy, ...

Minnie Hatch, 29, from Salt Lake City, had painful stomach cramps, and other symptoms for months before finding out she had Clostridioides difficile, or C. diff. These bacteria can grow out of control ...

A fecal transplant, as it's often called, is exactly what it sounds like. One person's, um, poop is put into another person's body. It works, scientists theorize, by re-introducing good microbes into ...

Dear Doctor: I'm not sure you'll take this question because of the subject matter, but it seems pretty important. Our dad had a fecal transplant as a last-ditch treatment for C. diff, and it worked.

Microbiota restoration may be a solution for effectively treating patients with Clostridiodes difficile infection, according to researchers. The primary outcome of this study found a 90% resolution of ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

Please provide your email address to receive an email when new articles are posted on . More patients in the bezlotoxumab group experienced recurrence vs. the placebo group (13% vs. 3%). Steroid use ...